Navigation Links
Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
Date:2/1/2012

search Center; Director, Colorectal Cancer Translational Research Program; and Chair, Ad Interim, Department of Cancer Biology. Dr. Ellis is vice-chair of the NCI Colon Cancer Task Force and serves on 8 editorial boards, including Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research. Dr. Ellis has served in leadership roles in major cancer societies including ASCO, American Association for Cancer Research, and the Society for Surgical Oncology.

Dr. Matthew Kulke is a world expert in neuroendocrine (NET) tumors. He is Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, where he leads the Carcinoid and Neuroendocrine Tumor Program. He has a leadership role in the Cancer and Leukemia Group B (CALGB) Gastrointestinal Cancer Committee, chairs the NCI NET Task Force and NCCN NET guidelines committees, and serves on the executive committee of the North American Neuroendocrine Tumor Society. Dr. Kulke has chaired multiple global pivotal studies exploring new therapies for NET.

About NKP-1339
NKP-1339 is a first-in-class small molecule anti-cancer compound that down-regulates GRP78, a known tumor survival and anti-apoptosis factor. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types. In the Phase I trial, antitumor activity was seen against multiple cancers, including NET.

About NKP-2235
NKP-2235 is a first-in-class orally available small molecule that targets the endoplasmic reticulum with a unique pattern of cytotoxicity. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly.

NKP-1339 and NKP-2235 were discovered by Professor Bernhard Keppler, University of Vienna, Austria.

About Niiki Pharma Inc.
Niiki Pharma (www.niikipharma.com) is a development focused oncology company specializing in first-in-class
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 /CNW/ - Health Minister Rona Ambrose today ... for donation over $2.5 million in personal protective equipment (PPE) ... global response to the Ebola outbreak in West ... shortage of equipment in the affected countries and has appealed ... in the affected countries. Personal protective equipment ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
Breaking Medicine Technology:Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3Pivotal Therapeutics Grants Incentive Stock Options 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5
... VIVUS, Inc. (Nasdaq: VVUS ) announced today ... the U.S. Food and Drug Administration (FDA) regarding its ... QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL ... approved in its present form.  The application seeks the ...
... Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said revenues from continuing operations ... versus the third quarter of 2009. Results ... first nine months of 2010 and 2009 exclude contributions ...
Cached Medicine Technology:FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16
(Date:9/16/2014)... Today The FSH Society, a world leader in ... Song,” featuring luminary pianist Steven Blier and two-time Grammy Award ... 2014 at the Tappan Hill Mansion, located on the former ... is proud to welcome Blier, who performs each year, and ... research. , FSHD, one of the most prevalent types of ...
(Date:9/16/2014)... Norfolk, VA (September 16, 2014) – ... desserts, announced today the launch of a limited edition ... October. In support of the American Cancer Society, an ... charitable donation in 2014 as well as help to ... among women in the United States. , The ...
(Date:9/16/2014)... 2014 (HealthDay News) -- Key connections between brain ... people with attention deficit hyperactivity disorder (ADHD), according ... within and between certain brain networks control ... the ability to focus on external tasks. This ... light on why those with ADHD are easily ...
(Date:9/16/2014)... 16, 2014 After working together for eight ... the premier fertility centers in the late 1990s and early ... to their hometown of New York City to launch Chelsea ... Genetics Labs. , Chelsea Fertility NYC offers full service ... in the New York Tri-State Area, and provides equal access ...
(Date:9/16/2014)... Dr. Randy Carlson and The Intentional Living ... Marriage event is coming to the Phoenix and Tucson ... better communicate, increase intimacy and have more fun with their ... and learning to strengthen your marriage and to rediscover intimacy,” ... Bible Church (Mesa), Saturday, Sept. 27 – Glendale Church of ...
Breaking Medicine News(10 mins):Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 2Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 3Health News:Study Sees Differences in Brain Connections of Kids With ADHD 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... data is showing a dramatic,reduction in the accidental ... more on one group,s 20-year effort to protect ... from Safe Kids Worldwide at:, http://media.medialink.com/WebNR.aspx?story=35058 , ... and,photos for free and unrestricted use at ...
... Brown & Toland Medical Group,today announced a strong financial ... on total revenues of $235 million., The medical ... performance and other related bonuses from health plans. The,medical ... $8.2,million in bonus payments to eligible physicians. In 2007 ...
... seem to cause drop in heart rate variability, researchers ... of a small study show that the electromagnetic field ... babies, Italian researchers report. , Whether these changes in ... could have implications for premature infants who can spend ...
... the Only Treatment Approved to Both Reduce Exacerbations ... ... 30 The,U.S. Food and Drug Administration today approved Advair ... powder),for the reduction of exacerbations in patients with chronic obstructive,pulmonary ...
... better way to distinguish acute leukemia patients who require aggressive ... therapy for cure., The study is published in the May ... an accompanying editorial. , Researchers say that changes in levels ... the kinds and amount of proteins they make, might predict ...
... April 30 Allscripts, the leading,provider of clinical ... improve healthcare, today announced results for the three,months ... ), Total revenue for the three months ... $65.0 million for the same period last year,increasing ...
Cached Medicine News:Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Molecular change may reveal risk of leukemia relapse 2Health News:Molecular change may reveal risk of leukemia relapse 3Health News:Allscripts Reports First Quarter 2008 Results 2Health News:Allscripts Reports First Quarter 2008 Results 3Health News:Allscripts Reports First Quarter 2008 Results 4Health News:Allscripts Reports First Quarter 2008 Results 5Health News:Allscripts Reports First Quarter 2008 Results 6Health News:Allscripts Reports First Quarter 2008 Results 7Health News:Allscripts Reports First Quarter 2008 Results 8Health News:Allscripts Reports First Quarter 2008 Results 9Health News:Allscripts Reports First Quarter 2008 Results 10
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: